98%
921
2 minutes
20
Background: Robot-assisted surgery is becoming increasingly used in pediatric oncology. The present study aimed to evaluate the feasibility and safety of robotic liver resection (RLR) for hepatic focal nodular hyperplasia (FNH) in children and compare surgical outcomes between RLR and open liver resection (OLR).
Methods: Pediatric patients with liver FNH undergoing lesion resection between January 2020 and June 2024 were included in the study. Patient demographics, operative details, postoperative outcomes, and follow-up were recorded and analyzed.
Results: A total of 20 patients were included in this study. Twelve patients underwent RLR and eight underwent OLR. In the RLR group, the median age was 93.1 months (range, 28-134 months) with a median weight of 32.4 kg (range, 9.7-80 kg). The median maximum tumor diameter at operation was 62.6 mm (range, 49-80 mm) and the median tumor volume was 94.3 mL (range, 35-254.1 mL). Operative time was 168.5 min (range, 116-245 min), intraoperative blood loss was 23.3 mL (range, 5-50 mL) and the length of postoperative hospital stay was 5.7 days (range, 4-11 days). There was a significant difference (<0.05) between the RLR and OLR groups for: age (93.1 months 137.6 months), maximum tumor diameter (62.6 mm 98 mm), tumor volume (94.3 mL 496.2 mL), operative time (168.5 min 281.4 min), blood loss (23.3 mL 288.7 mL), and length of postoperative hospital stay (5.7 days 9.5 days). There was a borderline significant association between surgical approach (RLR/OLR) and fluctuation in the magnitude of Alanine aminotransferase (ALT) (odds ratio=0.004, 95% confidence interval: 0.000 to 1.096, =0.05).
Conclusions: Our initial experience suggested that RLR for hepatic FNH in children was both feasible and safe. Tumors in the RLR group were significantly smaller than the OLR group: it proved possible to excise tumors larger than 250 mL in volume.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366609 | PMC |
http://dx.doi.org/10.1136/wjps-2025-001028 | DOI Listing |
Surg Endosc
September 2025
Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
Background: The implementation of minimally invasive liver surgery (MILS) for perihilar (PHC) and intrahepatic cholangiocarcinoma (IHC) remains limited and a systematic review including only comparative studies of MILS versus the open approach is lacking. This systematic review and meta-analysis aimed to assess the safety and efficacy of minimally invasive surgery in patients with hilar and intrahepatic cholangiocarcinomas.
Methods: Systematic review in the PubMed, Embase, and Cochrane databases for original studies comparing at least five patients undergoing MILS with open liver surgery for PHC and IHC.
Nihon Shokakibyo Gakkai Zasshi
September 2025
Department of Pathology, Japanese Red Cross Okayama Hospital.
An 86-year-old woman was under follow-up at the Breast Surgery Department of our hospital for postoperative treatment for right breast cancer. During this period, a 22-mm cystic mass was identified in the pancreatic head. Its size gradually increased, and she was eventually referred to our department.
View Article and Find Full Text PDFAnn Surg
September 2025
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Objective: To determine the incidence, clinical outcomes, and anatomical risk factors of portal vein (PV)-related complications after right lobe donor hepatectomy (RLDH).
Summary Background Data: With the increase in living donor liver transplantation, large-scale studies on donor morbidity have been conducted to ensure donor safety. However, reports evaluating PV-related complications following right hepatectomy in living donors are lacking.
Langenbecks Arch Surg
September 2025
Department of Surgery HBP Unit, Simone Veil Hospital, University of Reims Champagne-Ardenne, Troyes, France.
Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
HepatoBiliaryPancreatic Surgery, AOU Careggi, Department of Experimental and Clinical Medicine (DMSC), University of Florence, Florence, Italy.
Purpose: To build computed tomography (CT)-based radiomics models, with independent external validation, to predict recurrence and disease-specific mortality in patients with colorectal liver metastases (CRLM) who underwent liver resection.
Methods: 113 patients were included in this retrospective study: the internal training cohort comprised 66 patients, while the external validation cohort comprised 47. All patients underwent a CT study before surgery.